Gaucher Disease Type 3Symptoms, Doctors, Treatments, Advances & More
Learn About Gaucher Disease Type 3
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Texas Neurology, P.A.
Raphael Schiffmann is a Neurologist practicing medicine in Dallas, Texas. Dr. Schiffmann is rated as an Elite provider by MediFind in the treatment of Gaucher Disease Type 3. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Gaucher Disease Type 3, Fabry Disease, Gaucher Disease, and Leukodystrophy. Dr. Schiffmann is board certified in Neurology With Special Qualification In Child Neurology- American Board Of Psychiatry And Neurology and Neurology With Special Qualification In Child Neurology- American Board Of Psychiatry And Neurology/Neurology With Special Qualification In Child Neurology. Dr. Schiffmann is currently accepting new patients.
Radiology And Biomedical Imaging-New Haven-Yale Physicians Building
Pramod Mistry is a primary care provider, practicing in Internal Medicine in New Haven, Connecticut. Dr. Mistry is rated as an Elite provider by MediFind in the treatment of Gaucher Disease Type 3. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Gaucher Disease Type 1, Gaucher Disease, Gaucher Disease Type 3, Splenomegaly, and Splenectomy.
Ellen Sidransky is a Medical Genetics provider practicing medicine in Bethesda, Maryland. Dr. Sidransky is rated as an Elite provider by MediFind in the treatment of Gaucher Disease Type 3. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Gaucher Disease, Gaucher Disease Type 2, Gaucher Disease Type 3, and Farber Lipogranulomatosis.
Summary: Recent studies have has shown that magnetic resonance spectroscopy (MRS) can provide validated neuronal markers in patients with Type 1 GD (GD1) who are on stable therapy. However, alterations in neurometabolites in adult patients with GD3, who have established neurological involvement, are not well understood. The goal of this study is to characterize neurometabolite profiles in adult patients wi...